This protocol addresses the management of patients with myasthenia gravis who test positive for antibodies to muscle-specific kinase (MuSK-Ab+) — a serologically defined subgroup with distinct treatment considerations.
MuSK-Ab+ seropositivity characterises this patient population. The presence of antibodies to muscle-specific kinase identifies a subgroup that warrants a specific, evidence-based therapeutic approach within the broader myasthenia gravis spectrum.
Management in this setting involves initial immunotherapy — the choice and sequencing of agents within this approach are detailed in the full protocol.
The complete regimen, agent selection, and clinical algorithm are available via the structured protocol below.
DOI: 10.1212/WNL.0000000000011124
Rituximab should be considered as an early therapeutic option in patients with MuSK-Ab+ MG who have an unsatisfactory response to initial immunotherapy.
View source ↗